National Bank of Canada FI Trims Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

National Bank of Canada FI lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 94.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 387 shares of the biotechnology company’s stock after selling 7,140 shares during the period. National Bank of Canada FI’s holdings in Sarepta Therapeutics were worth $48,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Kovitz Investment Group Partners LLC increased its position in shares of Sarepta Therapeutics by 36.7% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 2,814 shares of the biotechnology company’s stock worth $322,000 after purchasing an additional 755 shares during the last quarter. Wellington Management Group LLP grew its stake in Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares in the last quarter. Soros Fund Management LLC bought a new stake in Sarepta Therapeutics in the third quarter valued at about $25,800,000. Stifel Financial Corp increased its holdings in Sarepta Therapeutics by 99.3% in the third quarter. Stifel Financial Corp now owns 37,207 shares of the biotechnology company’s stock valued at $4,647,000 after buying an additional 18,537 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in Sarepta Therapeutics by 9.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock valued at $94,148,000 after buying an additional 63,437 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Evercore ISI lowered their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Raymond James restated an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price objective for the company. Finally, Piper Sandler cut their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $178.71.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Trading Down 0.8 %

Sarepta Therapeutics stock opened at $125.76 on Wednesday. Sarepta Therapeutics, Inc. has a 12-month low of $89.92 and a 12-month high of $173.25. The stock has a market capitalization of $12.01 billion, a PE ratio of 100.61 and a beta of 0.77. The firm has a 50 day simple moving average of $123.42 and a 200-day simple moving average of $131.52. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.